Targeted drugs in the second line anticancer therapy of disseminated colorectal cancer

Abstract

For many years, colorectal cancer has been one of the most common tumor diseases in the world. However, treatment outcomes for patients with metastatic colorectal cancer have long remained quite poor. The development of targeted therapy had a significant impact on the improvement of long-term results of treatment of patients with metastatic colorectal cancer. The article provides basic recommendations on the use of targeted therapies in the second-line treatment of disseminated colorectal cancer, mechanism of action, efficacy, toxicity and specific applications. The authors tell about the new targeted agents which are now studied in clinical trials.

Keywords

• диссеминированный колоректальный рак вторая линия
• таргетная терапия бевацизумаб
• афлиберцепт цетуксимаб
• панитумумаб
• disseminated colorectal cancer
• second line
• targeted therapy
• bevacizumab
• aflibercept
• cetuximab
• panitumumab